US regulatory status: approved.
pharma · Alagille Syndrome · Progressive Familial Intrahepatic Cholestasis (PFIC) · MIRM
Mirum Pharmaceuticals International
Mirum Pharmaceuticals International B.V.
Mirum Pharmaceuticals International drug portfolio — 10 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
989 E Hillsdale Blvd., Suite 300, Foster City, CA 94404, US HQ
2018 Founded
436 Employees
Public company Type
MIRM · NYSE Ticker
Company details
- Status
- Public
- HQ
- 989 E Hillsdale Blvd., Suite 300, Foster City, CA 94404, US
- Founded
- 2018
- Employees
- 436
- Programs
- 25
- Drugs
- 10
- Patents
- 4
Mirum Pharmaceuticals International pipeline
Portfolio lens on 10 drugs and development assets — regulatory status, targets, and deep links to NovaPharmaNews drug profiles.
Mirum Pharmaceuticals International drug portfolio — 10 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
Drug portfolio
-
-
Development asset linked to Mirum Pharmaceuticals International in public FDA and regional records.
-
US regulatory status: approved. Mechanism: Dihydrofolate reductase inhibitor.
- Mechanism
- Dihydrofolate reductase inhibitor
-
US regulatory status: approved. Molecular target: Bile acid receptor.
- Target
- Bile acid receptor
- Mechanism
- Bile acid receptor FXR agonist
-
cholic acid
Alimentary tract and metabolism (A05)US regulatory status: approved. Mechanism: Unknown.
- Mechanism
- Unknown
-
US regulatory status: approved. Molecular target: Estrogen receptor.
- Target
- Estrogen receptor
- Mechanism
- Estrogen receptor alpha agonist
-
Development asset linked to Mirum Pharmaceuticals International in public FDA and regional records.
-
maralixibat
Alimentary tract and metabolism (A05)Alimentary tract and metabolism (A05) compound in Mirum Pharmaceuticals International's portfolio. Molecular target: Ileal sodium/bile acid cotransporter.
- Target
- Ileal sodium/bile acid cotransporter
- Mechanism
- Ileal bile acid transporter inhibitor
-
maralixibat chloride
Alimentary tract and metabolism (A05)US regulatory status: approved. Molecular target: Ileal sodium/bile acid cotransporter.
- Target
- Ileal sodium/bile acid cotransporter
- Mechanism
- Ileal bile acid transporter inhibitor
-
Development asset linked to Mirum Pharmaceuticals International in public FDA and regional records.